Bruker (NASDAQ:BRKR) Hits New 52-Week Low – Time to Sell?

Shares of Bruker Co. (NASDAQ:BRKR) hit a new 52-week low on Thursday . The stock traded as low as $54.54 and last traded at $54.55, with a volume of 1524371 shares traded. The stock had previously closed at $55.92.

Analyst Upgrades and Downgrades

BRKR has been the subject of several research reports. TD Cowen dropped their price target on Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research report on Wednesday, November 6th. Wells Fargo & Company dropped their price target on Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th. Wolfe Research cut Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. Citigroup dropped their price target on Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Finally, Barclays dropped their target price on Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Bruker has a consensus rating of “Moderate Buy” and an average price target of $79.36.

Bruker Trading Down 5.9 %

The company has a 50 day moving average of $62.60 and a 200-day moving average of $65.40. The company has a debt-to-equity ratio of 1.24, a quick ratio of 0.73 and a current ratio of 1.66. The stock has a market cap of $7.78 billion, a price-to-earnings ratio of 24.66, a price-to-earnings-growth ratio of 2.68 and a beta of 1.20.

Bruker (NASDAQ:BRKR) last posted its earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.61 by ($0.01). The firm had revenue of $864.40 million for the quarter, compared to analyst estimates of $866.46 million. Bruker had a return on equity of 21.52% and a net margin of 9.41%. Bruker’s revenue was up 16.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.74 EPS. On average, research analysts anticipate that Bruker Co. will post 2.4 earnings per share for the current year.

Institutional Investors Weigh In On Bruker

A number of hedge funds have recently bought and sold shares of BRKR. Covestor Ltd raised its position in shares of Bruker by 139.1% during the 1st quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock worth $34,000 after acquiring an additional 210 shares in the last quarter. First Horizon Advisors Inc. raised its position in shares of Bruker by 120.4% during the 2nd quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock worth $25,000 after acquiring an additional 218 shares in the last quarter. True Wealth Design LLC raised its position in shares of Bruker by 4,636.4% during the 3rd quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock worth $36,000 after acquiring an additional 510 shares in the last quarter. UMB Bank n.a. raised its position in shares of Bruker by 115.3% during the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock worth $46,000 after acquiring an additional 354 shares in the last quarter. Finally, Gordian Capital Singapore Pte Ltd acquired a new stake in shares of Bruker during the 2nd quarter worth about $52,000. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.